GlaxoSmithKline PLC is putting its faith in two high-volume, lower-risk businesses, vaccines and consumer health care, to stabilize the company ahead of what are expected to be challenging years for its pharmaceutical business.
GSK Positions To Dominate In Vaccines; Will The Bet Pay Off?
The British pharma outlined its strategy for winning as one of the world’s leading vaccines makers May 6, two months after completing the acquisition of Novartis’ vaccines business.
More from Clinical Trials
• By
The new global GCP guideline, ICH E6(R3), enables researchers and clinical trial administrators to tailor their documentation processes, but also opens the door for more scrutiny during GCP inspections.
• By
The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.